Guardant Blood Test Gains Medicare Coverage for Colon Cancer
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
colon-cancerscreening
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Medicare finalized coverage for Guardant Health's Shield blood-based colorectal cancer screening test on June 4, 2026. The decision, reported by MarketWatch, enables reimbursement for a test aimed at an estimated 50 million unscreened American adults. The Shield test detects tumor-derived DNA in blood with 83% sensitivity for colorectal cancer. Its approval creates a new pathway to screening for patients who avoid invasive colonoscopies, a method with over 95% sensitivity.
Colorectal cancer incidence has increased by 2% annually since 1995 for individuals under 55. The U.S. Preventive Services Task Force lowered its recommended screening age to 45 in 2021 to combat this trend. Medicare policy often sets precedent for private insurer coverage, influencing tens of billions in annual healthcare spending.
The coverage decision arrives as Medicare faces pressure to control costs and improve adherence to preventive care guidelines. Screening rates have stagnated below 70% for eligible adults. The last major Medicare coverage expansion for oncology screening was for multi-cancer early detection blood tests in early 2025. Guardant's test, specifically for colon cancer, enters a market dominated by Exact Sciences' Cologuard stool test and traditional colonoscopy procedures.
Guardant's Shield test demonstrated 83% sensitivity for colorectal cancer in a 20,000-patient study published in The New England Journal of Medicine in 2024. Specificity for advanced neoplasia was 90%. The traditional colonoscopy procedure typically achieves sensitivity above 95% and is considered the diagnostic gold standard.
Medicare reimbursement for the Shield test is set at approximately $500. This positions it between the $600-$800 average cost of a Cologuard test and the $1,200-$3,000 average cost of a screening colonoscopy. The total addressable non-invasive colorectal cancer screening market in the United States exceeds $20 billion annually. Exact Sciences reported $2.1 billion in Cologuard revenue for fiscal year 2025. Guardant's oncology testing revenue reached $789 million for the same period.
| Screening Method | Sensitivity for Cancer | Estimated Cost | Annual Screening Volume (U.S.) |
|---|---|---|---|
| Guardant Shield (Blood) | 83% | ~$500 | Newly covered, projected 5M+ |
| Exact Sciences Cologuard (Stool) | 92% | $600-$800 | ~10 million |
| Colonoscopy | >95% | $1,200-$3,000 | ~19 million |
The Medicare decision is a direct positive catalyst for Guardant Health (GH). The company's shares gained 12% in pre-market trading following the announcement. Analysts project Shield test revenue could exceed $500 million annually within three years, adding significant scale to Guardant's existing precision oncology business. The move also pressures providers reliant on colonoscopy volumes, including hospital systems like HCA Healthcare (HCA) and ambulatory surgery center operators.
Exact Sciences (EXAS) faces increased competitive pressure. While Cologuard has superior clinical sensitivity, the blood-based Shield test benefits from a more convenient sample collection method. Exact Sciences may need to accelerate development of its own blood-based test pipeline. Medical device firms selling colonoscopy equipment, such as Boston Scientific (BSX) and Medtronic (MDT), could see slower growth in procedural volumes if the non-invasive test adoption accelerates.
A key counter-argument is that blood tests may lead to lower adherence to follow-up colonoscopies for positive results, potentially delaying treatment. Investment flows are rotating into liquid biopsy and diagnostic firms, while healthcare services ETFs with heavy exposure to procedure volumes have seen outflows.
The Centers for Medicare & Medicaid Services will issue final payment determinations in the third quarter of 2026. Private insurers typically follow Medicare's lead within 6-12 months; watch for announcements from UnitedHealth Group (UNH) and Elevance Health (ELV).
Guardant Health reports Q2 2026 earnings on August 6, 2026. Initial commentary on Shield test commercial rollout and early physician adoption rates will be critical. Exact Sciences will report earnings on July 30, 2026, where management's response to the competitive threat will be scrutinized.
Key levels for Guardant Health (GH) stock are $48 as near-term support, with resistance at the $65 level last seen in 2025. A sustained break above $65 on volume would indicate strong conviction in the commercial opportunity. Exact Sciences (EXAS) needs to hold its 200-day moving average near $72 to maintain its long-term uptrend.
The Guardant Shield blood test demonstrated 83% sensitivity for detecting colorectal cancer in its pivotal clinical trial. A traditional colonoscopy, where a doctor visually inspects the colon with a camera, typically has a sensitivity above 95%. The colonoscopy remains the gold standard because it can both detect and remove precancerous polyps during the same procedure, which a blood test cannot do.
Medicare coverage validates the blood-based screening category, which is a net positive for the broader liquid biopsy sector, including companies like Freenome and GRAIL. However, it creates specific competitive pressure on Exact Sciences (EXAS), whose Cologuard stool test currently holds a dominant market share. Hospital and outpatient surgery center stocks may face headwinds if blood tests reduce colonoscopy volumes, impacting revenue for procedure-dependent providers.
Private insurers often adopt Medicare coverage decisions, but the timeline varies. Major national payers like Aetna (CVS) and Cigna (CI) typically initiate their own coverage reviews following a Medicare National Coverage Determination. Coverage could begin appearing in private plans in early 2027. The speed of adoption will depend on contracted pricing and Guardant's efforts to demonstrate the test's cost-effectiveness in reducing late-stage cancer treatment expenses.
Medicare's coverage of a blood-based colon cancer test disrupts a $20 billion screening market, benefiting liquid biopsy firms at the expense of traditional procedure providers.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.